Cancer Cell

Cancer Cell is a monthly peer-reviewed journal in oncology and cell biology published by Cell Press, an imprint of Elsevier, established in February 2002, covering cancer research at the cellular level and bridging foundational discoveries and clinical innovation, with a 2025 Journal Impact Factor of 56.1（Cancer Cell，癌细胞）是 Cell Press（爱思唯尔旗下）出版的月刊，聚焦肿瘤学与细胞生物学，2002 年 2 月创刊，涵盖细胞层面的癌症研究并连接基础发现与临床创新，2025 年影响因子为 56.1。

Scope

• It advances a systemic understanding of cancer as a dynamic interplay between tumor cells, the microenvironment, the microbiota, the nervous system and host physiology该刊推动以系统视角理解癌症，视其为肿瘤细胞、微环境、微生物群、神经系统与宿主生理之间的动态交互。
• It bridges foundational discoveries and clinical innovation through bidirectional translation该刊通过双向转化连接基础发现与临床创新。
• It integrates disciplines and transformative technologies including AI, spatial multi-omics, single-cell sequencing and functional genomics该刊整合多个学科与变革性技术，包括人工智能、空间多组学、单细胞测序与功能基因组学。
• It prioritizes studies that unravel tumor heterogeneity, immune evasion, metabolic reprogramming and therapeutic resistance该刊优先刊载揭示肿瘤异质性、免疫逃逸、代谢重编程与治疗耐受的研究。
• It emphasizes clinical trials with biological insights and preclinical work grounded in clinical hypotheses该刊重视兼具生物学洞见的临床试验，以及以临床假说为基础的前临床研究。
• It publishes reports of novel results in any area of cancer research, from molecular and cellular biology to clinical oncology, together with commentary on seminal findings in diagnosis and treatment该刊刊载癌症研究各领域的新颖结果，从分子与细胞生物学到临床肿瘤学，并就诊断与治疗的重要发现发表评述。

History

• It was established in February 2002 by Cell Press, and its first volume appeared that year该刊 2002 年 2 月由 Cell Press 创办，首卷于同年面世。^[1]
• Cell Press grew out of the journal Cell, founded in 1974 by Benjamin Lewin, and became an independent publisher that was acquired by Elsevier in 1999Cell Press 源自 Benjamin Lewin 于 1974 年创办的期刊 Cell，后成为独立出版社，并于 1999 年被爱思唯尔收购。
• The journal covers all aspects of cancer research at the cellular level该刊涵盖细胞层面的癌症研究各方面。
• It is published monthly该刊为月刊。
• Its editor-in-chief, Steve Mao, joined Cancer Cell in 2020 and became a publishing director at Cell Press in 2022其主编 Steve Mao 于 2020 年加入 Cancer Cell，2022 年起兼任 Cell Press 出版总监。
• Its journal impact factor was 44.5 in 2024 and 56.1 in 2025, after 48.8 in 2023其影响因子 2024 年为 44.5、2025 年为 56.1，此前 2023 年为 48.8。

Editors

• The editor-in-chief is Steve Mao, who holds a PhD in cell biology from UT Southwestern and did postdoctoral work at Cold Spring Harbor Laboratory and Harvard University现任主编 Steve Mao 拥有德州大学西南医学中心细胞生物学博士学位，并在冷泉港实验室与哈佛大学从事博士后研究。
• He was a senior editor at Cell and at Science before joining Cancer Cell in 2020, and since 2022 has also been a publishing director at Cell Press加入 Cancer Cell 之前，他曾任 Cell 与 Science 的资深编辑；自 2022 年起兼任 Cell Press 出版总监。
• He now manages a portfolio that includes Cancer Cell, Cell Metabolism, Cell Stem Cell, Developmental Cell, Immunity, Med, Molecular Cell and Neuron他现负责包括 Cancer Cell、Cell Metabolism、Cell Stem Cell、Developmental Cell、Immunity、Med、Molecular Cell 与 Neuron 在内的期刊群。
• The editorial team includes deputy editor Montserrat Rojo de la Vega, who joined in 2018 and works on cancer biology and NRF2 signalling, and scientific editor Cansu Cirzi, trained in molecular biology and genetics编辑团队包括 2018 年加入、关注癌症生物学与 NRF2 信号的副编辑 Montserrat Rojo de la Vega，以及分子生物学与遗传学出身的科学编辑 Cansu Cirzi。
• Submissions are handled by Cell Press professional editors, who select manuscripts for review, coordinate the peer review process and guide authors through revision稿件由 Cell Press 专业编辑处理，他们遴选送审稿件、组织同行评审并指导作者完成修订。
• Cell Press offers a multi-journal submission service, allowing authors to submit a manuscript to several Cell Press journals at the same timeCell Press 提供多刊投稿服务，作者可同时将稿件投给多家 Cell Press 期刊。
• Besides research articles on seminal findings in cancer research, diagnosis and treatment, the journal also publishes review and commentary content除就癌症研究、诊断与治疗的重要发现刊载研究论文外，该刊还发表综述与评述类文章。